» Articles » PMID: 24818853

Prostate Cancer in Young Men: an Important Clinical Entity

Overview
Journal Nat Rev Urol
Specialty Urology
Date 2014 May 14
PMID 24818853
Citations 122
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate cancer is considered a disease of older men (aged >65 years), but today over 10% of new diagnoses in the USA occur in young men aged ≤55 years. Early-onset prostate cancer, that is prostate cancer diagnosed at age ≤55 years, differs from prostate cancer diagnosed at an older age in several ways. Firstly, among men with high-grade and advanced-stage prostate cancer, those diagnosed at a young age have a higher cause-specific mortality than men diagnosed at an older age, except those over age 80 years. This finding suggests that important biological differences exist between early-onset prostate cancer and late-onset disease. Secondly, early-onset prostate cancer has a strong genetic component, which indicates that young men with prostate cancer could benefit from evaluation of genetic risk. Furthermore, although the majority of men with early-onset prostate cancer are diagnosed with low-risk disease, the extended life expectancy of these patients exposes them to long-term effects of treatment-related morbidities and to long-term risk of disease progression leading to death from prostate cancer. For these reasons, patients with early-onset prostate cancer pose unique challenges, as well as opportunities, for both research and clinical communities. Current data suggest that early-onset prostate cancer is a distinct phenotype-from both an aetiological and clinical perspective-that deserves further attention.

Citing Articles

Chest Pain as a Symptom of Early-Onset Metastatic Prostate Cancer: Exploring the Role of Screening.

Mohsin F, Boodhai B, Maharaj A, Levy N, Khan M, Sajid F Cureus. 2025; 17(1):e78143.

PMID: 40027043 PMC: 11867768. DOI: 10.7759/cureus.78143.


Association of cigarette use with risk of prostate cancer among US males: a cross-sectional study from NHANES 1999-2020.

Yang X, Chen H, Zhang J, Zhang S, Wu Y, Pang J BMC Public Health. 2025; 25(1):608.

PMID: 39948519 PMC: 11827229. DOI: 10.1186/s12889-025-21863-9.


Exploring the Epidemiological Characteristics and Survival Analysis Among Prostate Cancer Patients Under 50: A Seer-Based Population Study.

Mali B, Mali A, Mali A, Abdulrazzak M, Jobran A Health Sci Rep. 2025; 8(1):e70414.

PMID: 39867704 PMC: 11758148. DOI: 10.1002/hsr2.70414.


Risk factors for early readmission to hospital in patients with malignancy-related ascites: a retrospective cohort study.

Tian Z, Huang Z, Guo Y, Zhao X, Liu L, Yu C Front Oncol. 2024; 14:1409411.

PMID: 39411127 PMC: 11474032. DOI: 10.3389/fonc.2024.1409411.


Exploring Prostate Cancer Incidence Trends and Age Change in Cancer Registration Areas of Jiangsu Province, China, 2009 to 2019.

Zhou H, Hong X, Miao W, Wang W, Wang C, Han R Curr Oncol. 2024; 31(9):5516-5527.

PMID: 39330036 PMC: 11431764. DOI: 10.3390/curroncol31090408.


References
1.
Chen Y, Page J, Chen R, Giovannucci E . Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era. Prostate. 2008; 68(14):1582-91. PMC: 2574825. DOI: 10.1002/pros.20825. View

2.
Aly M, Wiklund F, Xu J, Isaacs W, Eklund M, DAmato M . Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. Eur Urol. 2011; 60(1):21-8. PMC: 4417350. DOI: 10.1016/j.eururo.2011.01.017. View

3.
Laitinen V, Wahlfors T, Saaristo L, Rantapero T, Pelttari L, Kilpivaara O . HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2013; 22(3):452-60. DOI: 10.1158/1055-9965.EPI-12-1000-T. View

4.
Carter H, Epstein J, Partin A . Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology. 1999; 53(1):126-30. DOI: 10.1016/s0090-4295(98)00466-x. View

5.
Nelson M, Wegmann D, Ehm M, Kessner D, St Jean P, Verzilli C . An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science. 2012; 337(6090):100-4. PMC: 4319976. DOI: 10.1126/science.1217876. View